AU3662300A - Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding - Google Patents
Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding Download PDFInfo
- Publication number
- AU3662300A AU3662300A AU36623/00A AU3662300A AU3662300A AU 3662300 A AU3662300 A AU 3662300A AU 36623/00 A AU36623/00 A AU 36623/00A AU 3662300 A AU3662300 A AU 3662300A AU 3662300 A AU3662300 A AU 3662300A
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- sex hormones
- uterine bleeding
- pharmaceutical composition
- useful
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011282 treatment Methods 0.000 title description 17
- 239000003163 gonadal steroid hormone Substances 0.000 title description 12
- 239000008194 pharmaceutical composition Substances 0.000 title description 10
- 206010046788 Uterine haemorrhage Diseases 0.000 title description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 14
- 229930182833 estradiol Natural products 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 239000000583 progesterone congener Substances 0.000 description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 206010030247 Oestrogen deficiency Diseases 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 150000000319 19-nortestosterones Chemical class 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 208000016599 Uterine disease Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001853 demegestone Drugs 0.000 description 1
- JWAHBTQSSMYISL-MHTWAQMVSA-N demegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 JWAHBTQSSMYISL-MHTWAQMVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960004913 dydrogesterone Drugs 0.000 description 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 229940012028 ethynodiol diacetate Drugs 0.000 description 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000606 medrogestone Drugs 0.000 description 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960004190 nomegestrol acetate Drugs 0.000 description 1
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 150000003128 pregnanes Chemical class 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 229960001584 promegestone Drugs 0.000 description 1
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Description
USE OF SEX HORMONES TO OBTAIN A NASAL PHARMACEUTICAL COMPOSITION THAT IS USEFUL IN THE TREATMENT OF UNDESIRABLE UTERINE BLEEDING The present invention relates to the use of sex hormones to obtain a pharmaceutical composition suitable for administration by the nasal route that is useful in the treatment of undesirable uterine bleeding phenomena in women. In therapies requiring the administration of sex hormones, uterine bleeding is very frequently observed outside the anticipated normal periods. Sex hormones may be administered in the treatment of disorders caused by oestrogen deficiency, and by oestrogen-deficiency symptoms associated especially with artificial or natural menopause. Such oestrogen deficiencies are likewise implicated in the occurrence of post-menopausal osteoporosis and in cerebral ageing phenomena and cardiovascular disorders. On the other hand, sex hormones are likewise administered in various doses for contraceptive purposes or in the treatment of amenorrhoea that is not associated with the menopause. The sex hormone-containing pharmaceutical compositions currently available to the medical profession are compositions that are suitable for oral administration (tablets), transcutaneous administration (gels, transdermal systems), parenteral administration (intramuscular injections, implants) or vaginal administration (creams, gels...). In a certain number of cases, those various types of treatment cause uterine bleeding, episodic or systematic, outside the anticipated periods of menstruation. The problem caused by such bleeding phenomena is such that it gives rise to worry among patients, who cannot themselves make a distinction between a side effect associated with the treatment and the occurrence of a uterine disorder. Such phenomena result in the attending physician requesting several kinds of supplementary investigations in order to determine the cause of the bleeding. When the bleeding is simply associated with -2 the treatment, the patients then want to turn to other types of treatment or prefer to discontinue the treatment. Bleeding thus appears to be one of the main causes of abandoning treatment. At present, all of the available types of treatment result in compliance difficulties, which hitherto have been only partially improved by the pharmaceutical forms currently available. The Applicant has now discovered that the use of sex hormones to obtain a pharmaceutical composition that is suitable for administration by the nasal route has surprisingly enabled treatment of the uterine bleeding observed outside menstrual periods. That surprising effect, achieved by nasal administration, has not been observed with the other formulations currently available to the medical profession. The improvement is all the more significant and of interest since it demonstrates long term effectiveness, it being possible, indeed, for treatment to be extended for several years. Among the sex hormones that can be used in the pharmaceutical compositions according to the invention there may be mentioned, without implying any limitation, natural steroid oestrogens, such as 17p-oestradiol (estradiol), oestrone and their derivatives, synthetic steroid oestrogens, such as ethynyl oestradiol, progestogens, such as progesterone, pregnanes derived from progesterone or from 17a-OH progesterone, such as dydrogesterone, chlormadinone acetate, medrogesterone, medroxyprogesterone acetate, norpregnanes, such as demegestone, promegestone, nomegestrol acetate or 19-nortestosterone compounds, such as norethisterone, ethynodiol diacetate, norgestrel, levonorgestrel, desogestrel, gestodene or norgestimate, or androgens, such as testosterone or dihydrotestosterone. The sex hormones preferred according to the invention are oestradiol and oestradiol/ progestogen mixtures.
-3 The pharmaceutical compositions suitable for the nasal administration of sex hormones are more specifically those which contain one or more sex hormones at doses that vary as a function of the requirements of the patient, and a cyclodextrin. Preferably, the pharmaceutical compositions according to the invention are characterised in that the cyclodextrin is a partially methylated cyclodextrin. A preferred composition according to the invention is one that contains oestradiol or an oestradiol/progestogen mixture and a cyclodextrin methylated partially and in random manner. When the composition contains a progestogen, the preferred progestogen is norethisterone. The preferred use according to the invention of the pharmaceutical compositions is in the treatment of undesirable uterine bleeding during menopause. By way of non-limiting example, a pharmaceutical composition suitable for the nasal administration of oestradiol was prepared and tested clinically in order to observe the treatment of uterine bleeding phenomena in menopausal women. The composition is a solution containing 0.21 g of oestradiol hemihydrate, 2.10 g of randomly and partially methylated cyclodextrin, 0.9 g of sodium chloride and purified water (ad 100 ml) after adjustment of the pH of the solution to 6. The solution was packaged in a bottle fitted with a dispensing pump enabling nasal sprays of 0.07 ml to be dispensed. Each spray thus delivers a dose of 150 pg of oestradiol hemihydrate. Clinical studies : Clinical studies were carried out on a population of patients who had been post menopausal for less than 10 years.
-4 The patients were divided into groups that, during a 28-day cycle, were given either: - a nasal oestradiol composition of the kind described hereinabove (oestradiol spray) and an oral placebo composition, or - an oral oestradiol formulation and a nasal placebo composition (placebo spray). In each group, the patients were administered with a progestogen for at least 10 to 14 days per cycle at the doses recommended for each product. The treatments were given in accordance with a randomisation code and lasted 3, 6 or 12 months. The daily dose administered for the nasal spray form is 300 jig of oestradiol (2 sprays per day), corresponding to a dose of 2 mg when administration is carried out by the oral route. Results In the course of the clinical studies, it was observed that uterine bleeding in patients from the group treated with the oestradiol nasal spray was approximately 30 % less frequent than in the patients treated with an oral form of oestradiol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9904022 | 1999-03-31 | ||
| FR9904022A FR2791572A1 (en) | 1999-03-31 | 1999-03-31 | Treating undesirable uterine bleeding, e.g. as side-effect of hormone therapy, by intranasal administration of estradiol |
| PCT/FR2000/000790 WO2000059447A2 (en) | 1999-03-31 | 2000-03-30 | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3662300A true AU3662300A (en) | 2000-10-23 |
Family
ID=9543854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU36623/00A Abandoned AU3662300A (en) | 1999-03-31 | 2000-03-30 | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1143978A2 (en) |
| JP (1) | JP2002541076A (en) |
| KR (1) | KR20010102464A (en) |
| CN (1) | CN1346273A (en) |
| AU (1) | AU3662300A (en) |
| BR (1) | BR0008577A (en) |
| CA (1) | CA2361885A1 (en) |
| EA (1) | EA200100801A1 (en) |
| FR (1) | FR2791572A1 (en) |
| HK (1) | HK1044486A1 (en) |
| HU (1) | HUP0200244A3 (en) |
| NO (1) | NO20014022D0 (en) |
| NZ (1) | NZ513672A (en) |
| PL (1) | PL356767A1 (en) |
| WO (1) | WO2000059447A2 (en) |
| ZA (1) | ZA200106689B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4383993A (en) * | 1980-05-30 | 1983-05-17 | University Of Kentucky Research Foundation | Nasal dosage forms containing natural female sex hormones |
| NL8801670A (en) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | PHARMACEUTICAL PREPARATION. |
| US5922699A (en) * | 1996-06-07 | 1999-07-13 | Pherin Corporation | 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function |
| AU726625B2 (en) * | 1996-07-23 | 2000-11-16 | Pherin Pharmaceuticals, Inc. | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
-
1999
- 1999-03-31 FR FR9904022A patent/FR2791572A1/en not_active Withdrawn
-
2000
- 2000-03-30 KR KR1020017011124A patent/KR20010102464A/en not_active Application Discontinuation
- 2000-03-30 CA CA002361885A patent/CA2361885A1/en not_active Abandoned
- 2000-03-30 BR BR0008577-4A patent/BR0008577A/en not_active IP Right Cessation
- 2000-03-30 CN CN00804471A patent/CN1346273A/en active Pending
- 2000-03-30 AU AU36623/00A patent/AU3662300A/en not_active Abandoned
- 2000-03-30 JP JP2000609012A patent/JP2002541076A/en active Pending
- 2000-03-30 HU HU0200244A patent/HUP0200244A3/en unknown
- 2000-03-30 WO PCT/FR2000/000790 patent/WO2000059447A2/en not_active Application Discontinuation
- 2000-03-30 PL PL00356767A patent/PL356767A1/en not_active Application Discontinuation
- 2000-03-30 NZ NZ513672A patent/NZ513672A/en not_active Application Discontinuation
- 2000-03-30 EP EP00915247A patent/EP1143978A2/en not_active Withdrawn
- 2000-03-30 EA EA200100801A patent/EA200100801A1/en unknown
-
2001
- 2001-08-14 ZA ZA200106689A patent/ZA200106689B/en unknown
- 2001-08-17 NO NO20014022A patent/NO20014022D0/en not_active Application Discontinuation
-
2002
- 2002-08-23 HK HK02106208.3A patent/HK1044486A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1143978A2 (en) | 2001-10-17 |
| PL356767A1 (en) | 2004-07-12 |
| HUP0200244A3 (en) | 2003-05-28 |
| WO2000059447A3 (en) | 2001-04-26 |
| NO20014022L (en) | 2001-08-17 |
| FR2791572A1 (en) | 2000-10-06 |
| WO2000059447A2 (en) | 2000-10-12 |
| CA2361885A1 (en) | 2000-10-12 |
| BR0008577A (en) | 2002-10-01 |
| EA200100801A1 (en) | 2002-04-25 |
| NO20014022D0 (en) | 2001-08-17 |
| CN1346273A (en) | 2002-04-24 |
| ZA200106689B (en) | 2002-11-14 |
| HUP0200244A2 (en) | 2002-07-29 |
| HK1044486A1 (en) | 2002-10-25 |
| KR20010102464A (en) | 2001-11-15 |
| NZ513672A (en) | 2001-09-28 |
| JP2002541076A (en) | 2002-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5827843A (en) | Preparation for substitution therapy, containing at least one progestogen and at least one estrogen | |
| KR960001371B1 (en) | Compounds containing progestogen and estrogen for | |
| JPH04290830A (en) | Prescribed contraceptive | |
| HU221169B1 (en) | Use of estrogen and antiprogestin for producing pharmaceutical compositions useful in hormon replacement therapy and kit containing the same | |
| JP2006096775A (en) | Composition for contraception | |
| US20020193356A1 (en) | Means and method for hormonal contraception | |
| HUT74428A (en) | Hormonal pharmaceutical compositions for contraception and treatment of acne | |
| KR20150058555A (en) | Management of breakthrough bleeding in extended hormonal contraceptive regimens | |
| JPH10513152A (en) | Periodic phase hormone regimen containing antiprogestin and progestin | |
| KR970704450A (en) | Use of a progesterone antagonist and gestagen to treat endometrial hyperplasia or uterine leiomyoma (Use of a Progesterone Antagonist and a Gestagen for Endometriosis or Leiomyomate Uteri) | |
| EP1293210B1 (en) | Means and method for hormonal contraception | |
| JP2942560B2 (en) | Composition for treating estrogen deficiency | |
| US20030176404A1 (en) | Progestogen-anti-progestogen regimens | |
| US20040198707A1 (en) | Means and method for hormonal contraception | |
| AU3662300A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding | |
| MXPA01008772A (en) | Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding | |
| AU729898B2 (en) | Transdermal therapeutic system having an active compound combination comprising oestriol | |
| CA2171460C (en) | Preparation for substitution therapy, containing at least one progestogen and at least one extrogen | |
| EP1178807B1 (en) | Use of org 33245 in combined intermittent hormone therapy and contraception | |
| JPH08508502A (en) | Method for treating osteoporosis and therapeutic composition | |
| US20080280861A1 (en) | Method of Female Contraception and a Kit For Use Therein | |
| TH134365B (en) | Drospirinone for hormone replacement therapy | |
| AU1848899A (en) | Preparation for substitution therapy, containing at least one progestogen and at least one estrogen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: LES LABORATOIRES SERVIER Free format text: THE FORMER OWNER WAS: ADIR ET COMPAGNIE |